Zydus Lifesciences Ltd Share Price
As on 08 June 2026 at 00:14 IST
Zydus Lifesciences Q1 FY26 Results:
Net profit for the period increased 3% to ₹1,467 crores in Q1 FY26, from ₹1,420 crores in Q1 FY25. Total income for the quarter increased 7% year-on-year to ₹6,729 crores from ₹6,271 crores.
About Zydus Lifesciences Ltd
Zydus Lifesciences Ltd., previously known as Cadila Healthcare Ltd., is a prominent Indian pharmaceutical company. Founded by Ramanbhai Patel and Indravadan Modi in the city of Ahmedabad, Gujarat, the company has a rich history dating back to 1952. Specializing in pharmaceutical research, Zydus Lifesciences has established itself as a significant player in the pharmaceutical landscape. The company offers a diverse portfolio of healthcare products. Their product range encompasses generic drugs, vaccines, diagnostics, and wellness products. Notable brands like Lipaglyn, SoviHep, and Exemptia have solidified the company's reputation in the market. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
20.20%
Over 6 Months
15.91%
Over 1 Year
16.44%
Over 3 Years
112.62%
Zydus Lifesciences Ltd Summary
Close ₹1,084.60
Open ₹1,070
High ₹1,098
Low ₹1,063.10
Volume 10,16,000
Net Turnover (in Cr) ₹110.37
52Wk High ₹1,115.50
52Wk Low ₹835.50
52Wk High / Low
835.50
1,115.50
Zydus Lifesciences Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹1,09,136.14
EPS (TTM) 36.70
Book Value (BV) 235.25
Div. Yield 0.09 %
P/E (TTM) 30.68
Price/Book Value 4.61
Delivery % 49.86 %
Face Value 1
Key Ratios
PE Ratio 15.43
PB Ratio 4.20
EV to Sales 6.44
PEG Ratio 0.23
ROA 19.38
ROE 31.29
Debt-Equity 0.39
Net Profit Margin 38.20
Operating Profit Margin 55.78
Zydus Lifesciences Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 23,511 | 19,831.50 | 17,424 | 15,334.60 | 14,449.10 |
| Total Expenses | 17,264.70 | 15,008.40 | 14,230.10 | 12,609.20 | 11,844.80 |
| Profit Before Tax | 6,026.70 | 4,808.90 | 2,589.70 | 2,838.10 | 2,399.20 |
| Profit After Tax | 4,614.80 | 3,831.40 | 2,001.90 | 2,326.40 | 2,205.60 |
| Operating Profit After Depreciation | 6,412.20 | 4,904.30 | 3,323.80 | 2,852.40 | 2,763.10 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 14,507.70 | 13,680.30 | 11,591.40 | 12,253.40 | 12,132.80 |
| Total Non Current Assets | 20,155.60 | 17,861 | 15,748.20 | 15,700.20 | 15,168.70 |
| Total Current Assets | 17,046.10 | 11,419.80 | 10,008.20 | 12,095.20 | 8,716 |
| Total Assets | 37,201.70 | 29,280.80 | 25,756.40 | 27,795.40 | 23,884.70 |
| Total Shareholder's Fund | 23,953.10 | 19,829.50 | 17,515.80 | 16,999.60 | 12,992.30 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 6,776.70 | 3,227.90 | 2,688.80 | 2,104.10 | 3,293 |
| Net Cash Used In Investing Activities | -8,377.10 | -1,492.30 | 1,177.80 | 1,137.10 | -834.60 |
| Net Cash Used In Financing Activities | 2,014.20 | -1,810.40 | -4,400.40 | -868.30 | -2,548.90 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 15,812.50 | 11,903.50 | 9,280 | 8,160.60 | 7,869.30 |
| Total Expenses | 8,367.80 | 7,655.10 | 7,044 | 6,677.40 | 5,993.30 |
| Profit Before Tax | 7,444.70 | 4,239.80 | 2,032.20 | 1,163.90 | 1,688.50 |
| Profit After Tax | 5,774.90 | 3,441.50 | 1,529.20 | 857.90 | 1,476.20 |
| Operating Profit After Depreciation | 7,908.60 | 4,639.10 | 2,514.20 | 1,618.10 | 1,946.90 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,202.10 | 4,376.60 | 4,184.10 | 4,335.90 | 4,112 |
| Total Non Current Assets | 17,002.20 | 16,173.50 | 13,405.40 | 10,902.60 | 12,431.90 |
| Total Current Assets | 15,314.70 | 7,911.30 | 7,158.20 | 6,837.40 | 6,031.70 |
| Total Assets | 32,316.90 | 24,084.80 | 20,563.60 | 17,740 | 18,463.60 |
| Total Shareholder's Fund | 21,190.10 | 15,716.50 | 13,639.40 | 13,240.50 | 12,744.50 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 3,114 | 2,000.30 | 1,078.20 | 1,310.70 | 2,227.20 |
| Net Cash Used In Investing Activities | -4,503.60 | -1,831.80 | -1,959.30 | 768.20 | -2,713.80 |
| Net Cash Used In Financing Activities | 1,384.50 | -300.80 | 827 | -1,709.80 | 255.30 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 7,587 | 6,864.50 | 6,123.20 | 6,573.70 | 6,527.90 |
| Total Expenses | 5,032.60 | 5,048.10 | 4,107.40 | 4,485.20 | 4,402.40 |
| Profit Before Tax | 1,659.70 | 1,353.40 | 1,687.40 | 1,920.60 | 1,672 |
| Profit After Tax | 1,341.30 | 965.10 | 1,233.40 | 1,486.60 | 1,248.80 |
| Operating Profit after Depreciation | 2,688.60 | 1,927.80 | 2,124.80 | 2,243.40 | 2,206.10 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 3,740.90 | 2,283.60 | 2,871.20 | 2,588.30 | 5,819.60 |
| Total Expenses | 1,751.80 | 2,084.60 | 1,719.30 | 2,002.90 | 2,046.90 |
| Profit Before Tax | 2,111 | 352.40 | 1,443.60 | 474.90 | 3,674.70 |
| Profit After Tax | 1,722 | 296.50 | 1,156.60 | 384.70 | 2,813.70 |
| Operating Profit after Depreciation | 2,484.20 | 672.80 | 1,693.40 | 742.50 | 3,958.10 |
Zydus Lifesciences Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,065.80
S2 1,047
S3 1,030.90
Pivot 1,081.90
R1 1,100.70
R2 1,116.80
R3 1,135.60
Moving Average
20 SMA 1,024.15
50 SMA 953.24
100 SMA 927.35
200 SMA 948.86
Zydus Lifesciences Ltd Corporate Actions
Zydus Lifesciences Ltd
₹11.0/Share
Announcement Date 25 Jul 2025
Record Date 25 Jul 2025
Div Yield 1100%
Zydus Lifesciences Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,779.35 | ₹4,26,925.67 |
| Divis Laboratories Ltd | ₹6,594.45 | ₹1,75,061.93 |
| Torrent Pharmaceuticals Ltd | ₹4,337.65 | ₹1,46,805.79 |
| Cipla Ltd | ₹1,397.75 | ₹1,12,910.32 |
| Dr Reddys Laboratories Ltd | ₹1,267.05 | ₹1,05,755.21 |
Zydus Lifesciences Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Kotak Flexi Cap Fund | 1.71% |
| ICICI Pru P.H.D Fund | 1.36% |
| Parag Parikh ELSS Tax Saver Fund | 1.29% |
| Parag Parikh Flexi Cap Fund | 1.21% |
| UTI-Nifty Next 50 Index Fund | 1.07% |
Zydus Lifesciences Ltd News
Zydus receives warning letter from USFDA for its Baddi site
03 Jun 2026, 12:11 pm
Zydus Lifesciences slips after Baddi units receives warning letter from US FDA
Zydus Lifesciences fell 2.24% to Rs 1053.10 after the company said that it has received a warning letter from the United States Food and Drug Administration (USFDA) relating to its formulation manufacturing facility located at Baddi, Himachal Pradesh
03 Jun 2026, 10:43 am
Zydus Lifesciences Ltd spurts 1.81%, up for five straight sessions
Zydus Lifesciences Ltd is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The stock is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma.
29 May 2026, 01:00 pm
Zydus Lifesciences concludes its investment in Torrent Urja 25
20 May 2026, 01:19 pm
Zydus Life ends higher after Q4 PAT rises 9% YoY; board approves Rs 1,100 cr buyback
Zydus Lifesciences gained 2.80% to end at Rs 1,018.95 after the company's consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25.
19 May 2026, 05:42 pm
Zydus Lifesciences Ltd Stock Analysis
- Annual revenue for Zydus Lifesciences Ltd increased by 32.84% to ₹15,812.50 crore in FY 2025 from ₹11,903.50 crore in FY 2024.
- Annual Net Profit for Zydus Lifesciences Ltd increased by 67.80% to ₹5,774.90 crore in FY 2025 from ₹3,441.50 crore in FY 2024.
- Promoter Shareholding in Zydus Lifesciences Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in December 2025 to 75% in March 2026.
- Zydus Lifesciences Ltd delivered a 1-year return of 16.44% compared to the Nifty 50, which provided a return of -4.89% as of the last trading session.
- Zydus Lifesciences Ltd share price moved up by 0.48% from its previous close of INR ₹1,084.60. The latest Zydus Lifesciences Ltd share price is INR ₹1,089.80.
- Zydus Lifesciences Ltd share price today has been at a low of 1,082.70 and a high of 1,097. Over the past 52 weeks, the Zydus Lifesciences Ltd share price has seen a low of 835.50 and a high of 1,115.50.
About Zydus Lifesciences Ltd
Zydus Lifesciences Ltd., previously known as Cadila Healthcare Ltd., is a prominent Indian pharmaceutical company. Founded by Ramanbhai Patel and Indravadan Modi in Ahmedabad, Gujarat, the company has a rich history dating back to 1952.
Specializing in pharmaceutical research, Zydus Lifesciences has established itself as a significant player in the pharmaceutical landscape. The company offers a diverse portfolio of healthcare products. Their product range encompasses generic drugs, vaccines, diagnostics, and wellness products. Notable brands like Lipaglyn, SoviHep, and Exemptia have solidified the company's reputation in the market.
The Patel family plays a pivotal role in the company's governance and strategic direction. Pankaj R. Patel holds the position of Chairman, while Sharvil P. Patel serves as the Managing Director of the company. The Patel family's major shareholding provides a strong foundation of stability, enabling the company to pursue ambitious goals and maintain robust operational strategies.
Zydus Lifesciences is one of the top pharmaceutical companies in India. However, it is not the biggest player globally. The company is managed by a team of managerial promoters who oversee its daily operations. They are –
The company's registered office is situated in Sur, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Ahmedabad, Gujarat. This strategic location reflects its national presence and corporate infrastructure. Meanwhile, the registrars are based at Amaranth Business Complex, Nr. St. Xaviers Corne.
Zydus Lifesciences' commitment to innovation and strong family leadership position it as a dynamic pharmaceutical enterprise that is continuously adapting to the evolving healthcare landscape.
The journey of Zydus Lifesciences began with a vision to make healthcare affordable and accessible to all. Ramanbhai Patel laid the foundation of the company with a commitment to providing high-quality medicines. In its early years, Zydus focused on developing essential medicines for the Indian market. The company's dedication to quality earned it a reputation as a reliable healthcare provider.
In the following decades, Zydus Lifesciences expanded its product portfolio and market reach. The company began developing a wide range of pharmaceutical products, including generic drugs, over-the-counter (OTC) medicines, and speciality therapeutics.
This diversification allowed Zydus to cater to various medical needs, from chronic diseases to everyday health concerns. The company's flagship products, such as Lipaglyn for diabetic dyslipidemia and Exemptia for rheumatoid arthritis, showcased its innovative capabilities.
Research and innovation have always been at the core of Zydus Lifesciences' strategy. The company has invested heavily in research and development (R&D) to develop new and improved treatments. Zydus operates multiple R&D centres where scientists work on cutting-edge technologies and novel drug delivery systems. This focus on innovation has resulted in several breakthrough products. It has also positioned Zydus as a leader in the pharmaceutical industry.
Quality is a hallmark of Zydus Lifesciences. The company adheres to stringent quality control measures at every stage of the manufacturing process. Zydus' commitment to quality is reflected in its manufacturing facilities. These facilities have the latest technology and comply with global regulatory standards. By maintaining high-quality standards, Zydus ensures that its products are safe, effective, and reliable.
The growth and success of Zydus Lifesciences can be attributed to the strong support from its promoters, the Patel family. The company's management, led by Sharvil P. Patel, has been instrumental in driving its strategic vision and growth. The Patel family's commitment to excellence and innovation has been a key factor in Zydus' journey. Their leadership has guided the company through various challenges and opportunities, ensuring sustained growth and success.
Zydus Lifesciences is recognized as one of the top pharmaceutical companies in India. The company's strong market position is a result of its comprehensive product portfolio and commitment to quality. Zydus' products are widely used and trusted by healthcare professionals and patients alike. While the company is a major player in the pharmaceutical industry, it continues to strive for greater heights, driven by its mission to improve healthcare outcomes.
Looking ahead, Zydus Lifesciences aims to further strengthen its position as a global leader in the pharmaceutical industry. The company plans to expand its product portfolio, explore new therapeutic areas, and enhance its R&D capabilities. Zydus is committed to leveraging advanced technologies to address unmet medical needs. The company's future vision is centred on improving patient outcomes and contributing to global healthcare advancements.
Overall, the journey of Zydus Lifesciences Ltd. is a testament to its unwavering commitment to quality, innovation, and patient-centric solutions.
Specializing in pharmaceutical research, Zydus Lifesciences has established itself as a significant player in the pharmaceutical landscape. The company offers a diverse portfolio of healthcare products. Their product range encompasses generic drugs, vaccines, diagnostics, and wellness products. Notable brands like Lipaglyn, SoviHep, and Exemptia have solidified the company's reputation in the market.
The Patel family plays a pivotal role in the company's governance and strategic direction. Pankaj R. Patel holds the position of Chairman, while Sharvil P. Patel serves as the Managing Director of the company. The Patel family's major shareholding provides a strong foundation of stability, enabling the company to pursue ambitious goals and maintain robust operational strategies.
Zydus Lifesciences is one of the top pharmaceutical companies in India. However, it is not the biggest player globally. The company is managed by a team of managerial promoters who oversee its daily operations. They are –
- Ganesh N Nayak
- Bhadresh K Shah
- Mukesh M Patel
The company's registered office is situated in Sur, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Ahmedabad, Gujarat. This strategic location reflects its national presence and corporate infrastructure. Meanwhile, the registrars are based at Amaranth Business Complex, Nr. St. Xaviers Corne.
Zydus Lifesciences' commitment to innovation and strong family leadership position it as a dynamic pharmaceutical enterprise that is continuously adapting to the evolving healthcare landscape.
The Zydus Lifesciences Journey
Zydus Lifesciences Ltd. was formerly known as Cadila Healthcare. It has carved out a significant place in the global pharmaceutical industry. Established in 1952 by Ramanbhai Patel, the company is headquartered in Ahmedabad, Gujarat, India. Over the decades, Zydus Lifesciences has grown from a small regional player to a leading pharmaceutical company known for its focus on innovation, quality, and patient-centric solutions.The journey of Zydus Lifesciences began with a vision to make healthcare affordable and accessible to all. Ramanbhai Patel laid the foundation of the company with a commitment to providing high-quality medicines. In its early years, Zydus focused on developing essential medicines for the Indian market. The company's dedication to quality earned it a reputation as a reliable healthcare provider.
In the following decades, Zydus Lifesciences expanded its product portfolio and market reach. The company began developing a wide range of pharmaceutical products, including generic drugs, over-the-counter (OTC) medicines, and speciality therapeutics.
This diversification allowed Zydus to cater to various medical needs, from chronic diseases to everyday health concerns. The company's flagship products, such as Lipaglyn for diabetic dyslipidemia and Exemptia for rheumatoid arthritis, showcased its innovative capabilities.
Research and innovation have always been at the core of Zydus Lifesciences' strategy. The company has invested heavily in research and development (R&D) to develop new and improved treatments. Zydus operates multiple R&D centres where scientists work on cutting-edge technologies and novel drug delivery systems. This focus on innovation has resulted in several breakthrough products. It has also positioned Zydus as a leader in the pharmaceutical industry.
Quality is a hallmark of Zydus Lifesciences. The company adheres to stringent quality control measures at every stage of the manufacturing process. Zydus' commitment to quality is reflected in its manufacturing facilities. These facilities have the latest technology and comply with global regulatory standards. By maintaining high-quality standards, Zydus ensures that its products are safe, effective, and reliable.
The growth and success of Zydus Lifesciences can be attributed to the strong support from its promoters, the Patel family. The company's management, led by Sharvil P. Patel, has been instrumental in driving its strategic vision and growth. The Patel family's commitment to excellence and innovation has been a key factor in Zydus' journey. Their leadership has guided the company through various challenges and opportunities, ensuring sustained growth and success.
Zydus Lifesciences is recognized as one of the top pharmaceutical companies in India. The company's strong market position is a result of its comprehensive product portfolio and commitment to quality. Zydus' products are widely used and trusted by healthcare professionals and patients alike. While the company is a major player in the pharmaceutical industry, it continues to strive for greater heights, driven by its mission to improve healthcare outcomes.
Looking ahead, Zydus Lifesciences aims to further strengthen its position as a global leader in the pharmaceutical industry. The company plans to expand its product portfolio, explore new therapeutic areas, and enhance its R&D capabilities. Zydus is committed to leveraging advanced technologies to address unmet medical needs. The company's future vision is centred on improving patient outcomes and contributing to global healthcare advancements.
Overall, the journey of Zydus Lifesciences Ltd. is a testament to its unwavering commitment to quality, innovation, and patient-centric solutions.
FAQ’s
What is the share price of Zydus Lifesciences Ltd today?
Zydus Lifesciences Ltd share price as on 7 Jun 2026 is ₹ 1089.8
What is the Market Cap of Zydus Lifesciences Ltd?
The market cap of Zydus Lifesciences Ltd stock is ₹1,09,136.14 Cr.
What is the PE Ratio of Zydus Lifesciences Ltd?
The Price to Earnings (P/E) Ratio of Zydus Lifesciences Ltd is 15.43
What is the PB Ratio of Zydus Lifesciences Ltd?
The Price to Book (P/B) Ratio of Zydus Lifesciences Ltd is 4.20
What is the 52 week high of Zydus Lifesciences Ltd Share Price?
The 52 week high of Zydus Lifesciences Ltd share price stands at ₹1,115.50
What is the 52 week low of Zydus Lifesciences Ltd Share Price?
The 52 week low of Zydus Lifesciences Ltd share price stands at ₹835.50
How can I buy shares of Zydus Lifesciences Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Zydus Lifesciences Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
